You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesmopressin
Accession NumberDB00035  (BTD00112, BTD00061, BIOD00112, BIOD00061)
TypeSmall Molecule
GroupsApproved
Description

Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery.

Structure
Thumb
Synonyms
1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin
1-deamino-8-D-arginine vasopressin
1-Desamino-8-D-arginine vasopressin
DDAVP
Desmopresina
Desmopressin
Desmopressine
Desmopressinum
Minirin
Stimate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ddavpspray.1 ug/mLnasalFerring Pharmaceuticals Inc.1978-02-21Not applicableUs
Ddavpinjection4 ug/mLintravenousFerring Pharmaceuticals Inc.1984-03-30Not applicableUs
Ddavpinjection4 ug/mLintravenousFerring Pharmaceuticals Inc.1984-03-30Not applicableUs
Ddavpsolution.1 mg/mLnasalSanofi Aventis U.S. Llc1978-02-21Not applicableUs
Ddavpsolution4 ug/mLintravenousSanofi Aventis U.S. Llc1984-03-30Not applicableUs
Ddavptablet.2 mg/1oralFerring Pharmaceuticals Inc.1995-09-06Not applicableUs
Ddavptablet.1 mg/1oralFerring Pharmaceuticals Inc.1995-09-06Not applicableUs
Ddavptablet.2 mg/1oralSanofi Aventis U.S. Llc1995-09-06Not applicableUs
Ddavpspray.1 ug/mLnasalFerring Pharmaceuticals Inc.1978-02-21Not applicableUs
Ddavptablet.1 mg/1oralSanofi Aventis U.S. Llc1995-09-06Not applicableUs
Ddavp Inj 4mcg/mlliquid4 mcgintramuscular; intravenous; subcutaneousFerring Inc1993-12-31Not applicableCanada
Ddavp Melttablet (orally disintegrating)240 mcgsublingualFerring Inc2009-05-05Not applicableCanada
Ddavp Melttablet (orally disintegrating)120 mcgsublingualFerring Inc2006-11-02Not applicableCanada
Ddavp Melttablet (orally disintegrating)60 mcgsublingualFerring Inc2006-11-02Not applicableCanada
Ddavp Rhinal Tubesolution.1 mg/mLnasalSanofi Aventis U.S. Llc1978-02-21Not applicableUs
Ddavp Rhinylesolution0.1 mgnasalFerring Inc1992-12-31Not applicableCanada
Ddavp Spraymetered-dose aerosol10 mcgnasalFerring Inc1989-12-31Not applicableCanada
Ddavp Tablets 0.1mgtablet0.1 mgoralFerring Inc1995-12-31Not applicableCanada
Ddavp Tablets 0.2mgtablet0.2 mgoralFerring Inc1995-12-31Not applicableCanada
Desmopressintablet0.2 mgoralMeliapharm Inc2011-07-272014-06-25Canada
Desmopressintablet0.1 mgoralMeliapharm Inc2011-07-272014-06-25Canada
Desmopressin Acetatespray10 ug/.1mLnasalPrasco Laboratories2014-01-01Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralFerring Pharmaceuticals Inc.2008-05-05Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralFerring Pharmaceuticals Inc.2008-05-05Not applicableUs
Desmopressin Acetatesolution4 ug/mLintravenousFerring Pharmaceuticals Inc.1999-10-26Not applicableUs
Desmopressin Acetatesolution4 ug/mLintravenousFerring Pharmaceuticals Inc.1999-10-26Not applicableUs
Desmopressin Acetatesolution.1 mg/mLnasalFerring Pharmaceuticals Inc.1999-08-10Not applicableUs
Desmopressin Acetatesolution4 ug/mLintravenousAmring Pharmaceuticals Inc.1999-10-26Not applicableUs
Desmopressin Acetatespray10 ug/.1mLnasalAmring Pharmaceuticals, Inc.2016-03-01Not applicableUs
Desmopressin Acetatesolution4 ug/mLintravenousAmring Pharmaceuticals Inc.1999-10-26Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralAmring Pharmaceuticals Inc.2008-05-05Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralAmring Pharmaceuticals Inc.2008-05-05Not applicableUs
Desmopressin Sprayspray, metered dose10 mcgnasalAa Pharma Inc2000-08-18Not applicableCanada
Desmopressin Tabletstablet0.2 mgoralRainbow Pharmaceuticals Inc2005-02-182012-08-03Canada
Desmopressin Tabletstablet0.1 mgoralRainbow Pharmaceuticals Inc2005-02-182012-08-03Canada
Minirintablet0.1 mgoralFerring Inc2003-01-152015-07-22Canada
Minirinmetered-dose aerosol10 mcgnasalFerring Inc2000-08-212005-08-02Canada
Nocdurnatablet (orally disintegrating)25 mcgsublingualFerring Inc2013-07-31Not applicableCanada
Nocdurnatablet (orally disintegrating)50 mcgsublingualFerring Inc2014-11-17Not applicableCanada
Nu-desmopressin Spraymetered-dose pump0.1 gnasalNu Pharm IncNot applicableNot applicableCanada
Octostim Liq Inj. 15mcg/mlliquid15 mcgintravenous; subcutaneousFerring Inc1995-12-31Not applicableCanada
Octostim Sprayspray150 mcgnasalFerring Inc1998-12-01Not applicableCanada
PMS-desmopressintablet0.2 mgoralPharmascience Inc2008-01-23Not applicableCanada
PMS-desmopressintablet0.1 mgoralPharmascience Inc2008-01-23Not applicableCanada
Stimatespray, metered1.5 mg/mLnasalCSL Behring LLC2011-09-16Not applicableUs
Teva-desmopressintablet0.2 mgoralTeva Canada Limited2007-07-16Not applicableCanada
Teva-desmopressintablet0.1 mgoralTeva Canada Limited2007-07-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-desmopressintablet0.2 mgoralApotex Inc2007-01-31Not applicableCanada
Apo-desmopressintablet0.1 mgoralApotex Inc2007-01-31Not applicableCanada
Desmopressin Acetatetablet.1 mg/1oralTeva Pharmaceuticals USA Inc2006-01-27Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralAmerican Health Packaging2012-10-08Not applicableUs
Desmopressin Acetatespray10 ug/1nasalApotex Corp.2005-01-27Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralApotex Corp.2006-03-07Not applicableUs
Desmopressin Acetatesolution.1 mg/mLnasalBauch & Lomb Incorporated1999-01-25Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralBlue Point Laboratories2014-02-27Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralApotex Corp.2006-03-07Not applicableUs
Desmopressin Acetateinjection4 ug/mLintravenousTeva Parenteral Medicines, Inc.1997-11-01Not applicableUs
Desmopressin Acetatesolution.1 mg/mLnasalPhysicians Total Care, Inc.2006-05-22Not applicableUs
Desmopressin Acetateinjection4 ug/mLintravenousTeva Parenteral Medicines, Inc.1997-11-01Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralAmerican Health Packaging2010-01-122015-12-29Us
Desmopressin Acetatetablet.1 mg/1oralBlue Point Laboratories2014-02-27Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralPhysicians Total Care, Inc.2007-07-19Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-17Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralAmerican Health Packaging2010-01-122015-12-29Us
Desmopressin Acetatetablet.2 mg/1oralbryant ranch prepack2011-08-15Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralMylan Institutional Inc.2007-12-26Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralActavis Pharma, Inc.2011-08-15Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralGlenmark Pharmaceuticals Inc.,Usa2015-05-28Not applicableUs
Desmopressin Acetateinjection, solution4 ug/mLintravenous; subcutaneousSun Pharmaceutical Industries Limited2013-01-30Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralAv Pak2013-07-24Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralActavis Pharma, Inc.2011-08-15Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralGlenmark Pharmaceuticals Inc.,Usa2015-05-28Not applicableUs
Desmopressin Acetatesolution.1 mg/mLnasalSun Pharmaceutical Industries Limited2012-04-14Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralAv Pak2013-07-24Not applicableUs
Desmopressin Acetateinjection, solution4 ug/mLintravenous; subcutaneousHospira, Inc.2000-08-28Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralCarilion Materials Management2006-01-27Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralAmerican Health Packaging2015-09-15Not applicableUs
Desmopressin Acetatesolution.1 mg/mLnasalSun Pharma Global FZE2013-12-24Not applicableUs
Desmopressin Acetatetablet.2 mg/1oralTeva Pharmaceuticals USA Inc2006-01-27Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralAmerican Health Packaging2012-10-08Not applicableUs
Desmopressin Acetatetablet.1 mg/1oralAmerican Health Packaging2015-09-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdiuretinFerring
DesmoMeltFerring
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Desmopressin acetate
Thumb
  • InChI Key: MLSVJHOYXJGGTR-IFHOVBQLSA-N
  • Monoisotopic Mass: 1128.448084334
  • Average Mass: 1129.269
DBSALT000044
Desmopressin acetate trihydrate
ThumbNot applicableDBSALT001154
Categories
UNIIENR1LLB0FP
CAS number16679-58-6
WeightAverage: 1069.217
Monoisotopic: 1068.426954962
Chemical FormulaC46H64N14O12S2
InChI KeyInChIKey=NFLWUMRGJYTJIN-NXBWRCJVSA-N
InChI
InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
IUPAC Name
(2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide
SMILES
NC(=O)CC[C@@H]1NC(=O)[[email protected]](CC2=CC=CC=C2)NC(=O)[[email protected]](CC2=CC=C(O)C=C2)NC(=O)CCSSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentCyclic peptides
Alternative Parents
Substituents
  • Cyclic alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • Macrolactam
  • Alpha-amino acid amide
  • N-substituted-alpha-amino acid
  • Pyrrolidine-2-carboxamide
  • Pyrrolidine carboxylic acid or derivatives
  • N-acylpyrrolidine
  • Phenol
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Cyclic alcohol
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Primary carboxylic acid amide
  • Organic disulfide
  • Lactam
  • Guanidine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboximidamide
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationOral formulations may be used to manage primary nocturnal enuresis in adults and vasopressin sensitive diabetes insipidus, and for control of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Intranasal and parenteral formulations may be used to manage spontaneous or trauma-induced bleeds (e.g. hemarthrosis, intramuscular hematoma, mucosal bleeding) in patients with hemophilia A or von Willebrand's disease Type I. May also be used parenterally to prevent or treat bleeding in patients with uremia.
PharmacodynamicsDesmopressin is a synthetic analogue of the natural antidiuretic hormone (ADH or vasopressin) that is produced by the hypothalamus and stored in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. It also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. The efficacy of desmopressin for managing bleeds in patients with hemophilia A or von Willebrand’s disease Type I arises from its ability to elicit dose-dependent increases in plasma factor VIII (antihemophilic factor), plasminogen activator, and to a lesser extent, factor VIII-related antigen and ristocetin cofactor activities; these changes improve blood clotting.
Mechanism of actionDesmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. Compared to natural ADH, desmopressin elicits a great antidiuretic response on weight basis.
Related Articles
AbsorptionMinimally absorbed from the GI tract (average absolute bioavailability = 0.08-0.16%). 10-20% absorbed from nasal mucosa.
Volume of distributionNot Available
Protein binding50%
Metabolism

Metabolic fate unknown. Is not affected by liver microsomal cytochrome P450 enzymes.

Route of eliminationNot Available
Half lifeOral t1/2=1.5-2.5 hours. Intranasal t1/2=3.3-3.5 hours. IV t1/2 is biphasic: initial t1/2=7.8 minutes, terminal t1/2=0.4-4 hours.
ClearanceNot Available
ToxicityOverdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdominal pain, facial flushing, dizziness, dry mouth, and hyponatremia. Nasal congestion and rhinitis have been reported with nasal spray formulations.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7979
Blood Brain Barrier-0.8866
Caco-2 permeable-0.7612
P-glycoprotein substrateSubstrate0.8242
P-glycoprotein inhibitor INon-inhibitor0.7864
P-glycoprotein inhibitor IINon-inhibitor0.9237
Renal organic cation transporterNon-inhibitor0.5915
CYP450 2C9 substrateNon-substrate0.7833
CYP450 2D6 substrateNon-substrate0.7901
CYP450 3A4 substrateNon-substrate0.5497
CYP450 1A2 substrateNon-inhibitor0.8383
CYP450 2C9 inhibitorNon-inhibitor0.7906
CYP450 2D6 inhibitorNon-inhibitor0.8735
CYP450 2C19 inhibitorNon-inhibitor0.765
CYP450 3A4 inhibitorNon-inhibitor0.7663
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9331
Ames testNon AMES toxic0.6679
CarcinogenicityNon-carcinogens0.8428
BiodegradationNot ready biodegradable0.9445
Rat acute toxicity2.7183 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.83
hERG inhibition (predictor II)Inhibitor0.6036
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Ferring pharmaceuticals inc
  • Bausch and lomb pharmaceuticals inc
  • Apotex inc richmond hill
  • Csl behring llc
  • Apotex inc etobicoke site
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Solutionintravenous4 ug/mL
Spraynasal.1 ug/mL
Tabletoral.1 mg/1
Tabletoral.2 mg/1
Liquidintramuscular; intravenous; subcutaneous4 mcg
Tablet (orally disintegrating)sublingual120 mcg
Tablet (orally disintegrating)sublingual240 mcg
Tablet (orally disintegrating)sublingual60 mcg
Solutionnasal.1 mg/mL
Solutionnasal0.1 mg
Metered-dose aerosolnasal10 mcg
Tabletoral0.1 mg
Tabletoral0.2 mg
Injectionintravenous4 ug/mL
Injection, solutionintravenous; subcutaneous4 ug/mL
Spraynasal10 ug/.1mL
Spraynasal10 ug/1
Spray, metered dosenasal10 mcg
Tablet (orally disintegrating)sublingual25 mcg
Tablet (orally disintegrating)sublingual50 mcg
Metered-dose pumpnasal0.1 g
Liquidintravenous; subcutaneous15 mcg
Spraynasal150 mcg
Spray, meterednasal1.5 mg/mL
Prices
Unit descriptionCostUnit
Stimate 1.5 mg/ml nasal spray334.2USD ml
Ddavp 0.01% nasal spray50.76USD ml
Ddavp 4 mcg/ml ampul43.27USD ml
Desmopressin 0.1 mg/ml spray39.6USD ml
Ddavp 0.1 mg/ml Solution21.26USD ml
Octostim 150 mcg/dose Metered Dose Spray17.39USD dose
Ddavp 4 mcg/ml11.33USD ml
Desmopressin ac 4 mcg/ml amp7.28USD ml
Desmopressin ac 4 mcg/ml vial7.08USD ml
Ddavp 0.2 mg tablet6.43USD tablet
Ddavp 0.1 mg tablet4.47USD tablet
Desmopressin acetate 0.2 mg tablet4.44USD tablet
Desmopressin acetate 0.1 mg tablet3.08USD tablet
Ddavp 0.2 mg Tablet2.98USD tablet
Ddavp 10 mcg/dose Metered Dose Spray2.13USD dose
Apo-Desmopressin 0.2 mg Tablet1.67USD tablet
Novo-Desmopressin 0.2 mg Tablet1.67USD tablet
Pms-Desmopressin 0.2 mg Tablet1.67USD tablet
Ddavp 0.1 mg Tablet1.49USD tablet
Apo-Desmopressin 10 mcg/dose Metered Dose Spray1.48USD dose
Apo-Desmopressin 0.1 mg Tablet0.83USD tablet
Novo-Desmopressin 0.1 mg Tablet0.83USD tablet
Pms-Desmopressin 0.1 mg Tablet0.83USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2484724 No2007-01-162023-05-07Canada
CA2486833 No2005-08-022024-04-30Canada
US5500413 No1993-06-292013-06-29Us
US7022340 No2003-04-302023-04-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.11 mg/mLALOGPS
logP-1ALOGPS
logP-6.1ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)9.5ChemAxon
pKa (Strongest Basic)11.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area435.41 Å2ChemAxon
Rotatable Bond Count19ChemAxon
Refractivity279.78 m3·mol-1ChemAxon
Polarizability106.19 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, “High purity desmopressin produced in large single batches.” U.S. Patent US5674850, issued November, 1991.

US5674850
General References
  1. Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. [PubMed:11380629 ]
External Links
ATC CodesH01BA02
AHFS Codes
  • 68:28.00
PDB EntriesNot Available
FDA labelDownload (90.1 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcenocoumarolDesmopressin may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Desmopressin is combined with Acetylsalicylic acid.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Desmopressin is combined with Aminosalicylic Acid.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Desmopressin.
Bismuth SubsalicylateThe risk or severity of adverse effects can be increased when Desmopressin is combined with Bismuth Subsalicylate.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.
CaffeineThe risk or severity of adverse effects can be increased when Desmopressin is combined with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Desmopressin.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Desmopressin.
DemeclocyclineThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Desmopressin.
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Desmopressin.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Desmopressin is combined with Dihydrocodeine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.
DuloxetineDuloxetine may increase the antiplatelet activities of Desmopressin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Desmopressin.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Desmopressin.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Desmopressin.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Desmopressin.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.
LithiumThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Desmopressin is combined with Magnesium salicylate.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Desmopressin.
MilnacipranMilnacipran may increase the antiplatelet activities of Desmopressin.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Desmopressin.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Desmopressin.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Desmopressin.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Desmopressin.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.
Repository corticotropinThe risk or severity of adverse effects can be increased when Repository corticotropin is combined with Desmopressin.
SalsalateThe risk or severity of adverse effects can be increased when Desmopressin is combined with Salsalate.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.
TolvaptanThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Desmopressin.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.
VenlafaxineVenlafaxine may increase the antiplatelet activities of Desmopressin.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Desmopressin.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Desmopressin.
WarfarinDesmopressin may increase the anticoagulant activities of Warfarin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name:
AVPR2
Uniprot ID:
P30518
Molecular Weight:
40278.57 Da
References
  1. Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. [PubMed:18761325 ]
  2. Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.
Gene Name:
AVPR1A
Uniprot ID:
P37288
Molecular Weight:
46799.105 Da
References
  1. Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. [PubMed:10731046 ]
  2. Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. [PubMed:10594321 ]
  3. Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. [PubMed:8957254 ]
  4. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
Gene Name:
AVPR1B
Uniprot ID:
P47901
Molecular Weight:
46970.345 Da
References
  1. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460 ]
  2. Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. [PubMed:14971638 ]
  3. Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8. [PubMed:18655906 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:08